⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 17, 2018Lung CancerOpen Access

Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer

Makoto Nishio Kazuhiko Nakagawa Tetsuya Mitsudomi Nobuyuki Yamamoto Tomohiro Tanaka Hiroshi Kuriki Ali Zeaiter Tomohide Tamura

View Full Paper

Ask AI

Bookmark

Share

Abstract

Alectinib appears to avert the progression of CNS metastases in patients with ALK-positive NSCLC and baseline CNS metastases, and to prevent the development of new CNS lesions in patients without baseline CNS disease.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nishio et al. (2018) studied this question.

synapsesocial.com/papers/69dee0d15e217d93a5558da1 https://doi.org/10.1016/j.lungcan.2018.04.015

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Clinical Experience With Crizotinib in Patients With Advanced <i>ALK</i>-Rearranged Non–Small-Cell Lung Cancer and Brain MetastasesRetrospective Study · 2015 · 600 citations
2Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridarOriginal Research · 2013 · 143 citations
3Alectinib in Crizotinib-Refractory <i>ALK-</i>Rearranged Non–Small-Cell Lung Cancer: A Phase II Global StudyEarly-Phase Clinical Trial · 2015 · 580 citations
4Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung CancerCohort Study · 2017 · 2,525 citations
5Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLCEarly-Phase Clinical Trial · 2017 · 25 citations

More from Lung Cancer

Second-line therapy in extensive-stage small cell lung cancer: an unmet need highlighted by real-world evidence from the LALUCA registryWed,
Long-term efficacy and adherence of a lung cancer screening strategy with extended LDCT intervals: Results from the BioMILD trialMon,
Outcomes of long-term responders to immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). A retrospective regional studySun,
Longitudinal transcriptomic profiling of paired early and metastatic EGFR-mutant lung adenocarcinomas reveals molecular programs associated with disease progressionSun,
Discordance in pleural mesothelioma response classification and modelling of impact on clinical trialsTue,